Health-Related Quality of Life with Mezigdomide, Carfilzomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase 3 SUCCESSOR-2 Trial (IMS 2026) - Sep 11, 2026 - Abstract #PA-220; Pres time: Sep 23, 2026; P3 | "Introduction: Interim results from the phase 3 SUCCESSOR-2 study showed that adding mezigdomide (Mezi) to carfilzomib-dexamethasone (Kd) significantly prolonged progression-free survival (PFS) versus Kd alone in patients (pts) with relapsed/refractory multiple myeloma (RRMM) previously treated with anti-CD38 monoclonal antibodies (mAbs) and lenalidomide (LEN). Adding Mezi to Kd in pts with RRMM did not meaningfully compromise pt-reported global QoL, physical or role functioning, pain, fatigue, disease symptoms, or perceived treatment side effects. Together with the reported PFS benefit, these findings support MeziKd as improving disease control without a broad HRQoL trade-off."
Clinical • HEOR • P3 data • Hematological Malignancies • Multiple Myeloma
|
|
Hang Quach1; Paul G. Richardson2; Fredrik Schjesvold3; Chengcheng Fu4; Monique A. Hartley-Brown2; Cesar Augusto Gomez5; Donna Reece6; Gabor Mikala7; Omar Alkharabsheh8; Christopher Parrish9; Nicole Clarke10; Amir Samuel10; Amol Dhamane10; Jessica Katz10; Shien Guo11; Ling Shi11; Meletios A. Dimopoulos12
|